Erratum to "Bispecific Antibody-Bound T Cells as a Novel Anticancer Immunotherapy" [Biomol. Ther. 30 (2022) 418-426]

Jaewon Cho¹, Nara Tae², Jae-Hee Ahn¹, Sun-Young Chang³, Hyun-Jeong Ko^{1

2}, Dae Hee Kim^{1

2}

Affiliations

¹ Department of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea.
² Kangwon Institute of Inclusive Technology, Kangwon National University, Chuncheon 24341, Republic of Korea.
³ College of Pharmacy, Ajou University, Suwon 16499, Republic of Korea.

Published Erratum

Jaewon Cho et al. Biomol Ther (Seoul). 2024.

. 2024 May 1;32(3):400-401.

doi: 10.4062/biomolther.2024.003.

Jaewon Cho¹, Nara Tae², Jae-Hee Ahn¹, Sun-Young Chang³, Hyun-Jeong Ko^{1

2}, Dae Hee Kim^{1

2}

¹ Department of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea.
² Kangwon Institute of Inclusive Technology, Kangwon National University, Chuncheon 24341, Republic of Korea.
³ College of Pharmacy, Ajou University, Suwon 16499, Republic of Korea.

No abstract available

Figures

Bispecific Antibody-Bound T Cells as a Novel Anticancer Immunotherapy.
Cho J, Tae N, Ahn JH, Chang SY, Ko HJ, Kim DH. Cho J, et al. Biomol Ther (Seoul). 2022 Sep 1;30(5):418-426. doi: 10.4062/biomolther.2022.015. Epub 2022 May 17. Biomol Ther (Seoul). 2022. PMID: 35577765 Free PMC article.